all report title image
  • Published On : Nov 2022
  • Code : CMI5371
  • Industry : Pharmaceutical
  • Pages : 102
  • Formats :

Mesalazine is an aminosalicylate drug used to treat mild to moderate active ulcerative colitis and maintain remission once achieved. Mesalazine is an anti-inflammatory agent, structurally related to salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is used in the treatment of inflammatory bowel diseases like ulcerative colitis and Crohn’s disease. Ulcerative colitis is a type of chronic inflammatory bowel disease that causes inflammation of the large intestine lining (colon). It produces ulcers on the colon's lining, which may cause bleeding and discharge of pus and mucus. Mesalazine works by inhibiting the production of certain chemical substances such as prostaglandins that cause pain and swelling that helps in reducing inflammation (redness and swelling) in the intestines and provides relief from symptoms such as stomach pain or bleeding.

China mesalazine market is estimated to be valued at US$ 51.6 million in 2022 and is expected to exhibit a CAGR of 3.1% during the forecast period (2022-2030).

Figure 1. China Mesalazine Market Share (%), by Route of Administration, 2022

China Mesalazine  | Coherent Market Insights

China Mesalazine Market - Driver

Increasing inorganic strategies, such as product launches by key market players, is expected to drive the growth of China mesalazine market. For instance, in July 2021, Tillotts Pharma AG, a pharmaceutical company, launched Asacol 800 mg tablets (mesalazine) as the first-line treatment for mild to moderate Ulcerative Colitis (UC) in China. It will strength mesalazine tablet formulation to the Chinese market to optimize the therapeutic options of patients living with ulcerative colitis in China.

CMI table icon

China Mesalazine Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 51.6 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 3.1% 2030 Value Projection: US$ 65.9 Mn
Geographies covered:
  • China
Segments covered:
  • By Route of Administration: Oral, Rectal
  • By Application: Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Disease
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Zhejiang Hengkang Pharmaceutical Co. Ltd., Jiangsu Jubang Pharmaceutical Co., Ltd., ALP Pharm Beijing Co., Ltd., Shanghai Pharmaceuticals Holding Co Ltd., Heilongjiang Tianhong Pharmaceutical Co., Ltd., AbbVie Inc., F. Hoffmann-La Roche AG, Takeda Pharmaceuticals Company Limited, GSK Plc., Tillotts Pharma AG, Novartis AG, Salix Pharmaceuticals, FERRING B.V., Viatris Inc., and Dr. Falk Pharma GmbH

Growth Drivers:
  • Increasing inorganic strategies such as product launches by key market players
Restraints & Challenges:
  • Availability of alternatives for mesalazine

Figure 2. China Mesalazine Market Share (%), by Application, 2022

China Mesalazine  | Coherent Market Insights

China Mesalazine Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020.

The COVID-19 can affect the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a positive impact on China mesalazine market. For instance, according to the data published in May 2020 by the National Center for Biotechnology Information, the COVID-19 pandemic affected patients with Inflammatory Bowel Disease (IBD) medically and psychosocially. Most patients with IBD experienced disease during the early and current phases of the outbreak and those individuals did not have to change their medications.

China Mesalazine Market: Key Developments

Market players are engaged in joint ventures which is expected to drive China mesalazine market growth over the forecast period. For instance, in November 2022, Alembic Pharmaceutical Limited, a pharmaceutical company, announced that it had received approval from the U.S. Food and Drug Administration (U.S. FDA) for the Abbreviated New Drug Application (ANDA) for Mesalazine extended–release capsules of strength 0.375 g.

China Mesalazine Market: Restraint

The availability of alternatives for mesalazine is expected to hamper the growth of China mesalazine market over the forecast period. Aminosalicylate (5-ASA) is considered the first line of treatment for ulcerative colitis. Moreover, other drug classes are indicated for the treatment of ulcerative colitis, inflammatory bowel disease, and Crohn’s disease. They are Corticosteroids, Immunomodulators, Targeted Synthetic Small Molecules (Immunosuppressants), and Biologic/Biosimilar Therapies (Monoclonal Antibodies). Furthermore, the introduction of biosimilars has revolutionized the control of Ulcerative Colitis (UC). It is a biological treatment for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. These medicines are less expensive than other drugs, making them more accessible to people in China.

China Mesalazine Market - Key Players

Major players operating in China mesalazine market include Zhejiang Hengkang Pharmaceutical Co. Ltd., Jiangsu Jubang Pharmaceutical Co., Ltd., ALP Pharm Beijing Co., Ltd., Shanghai Pharmaceuticals Holding Co Ltd., Heilongjiang Tianhong Pharmaceutical Co., Ltd., AbbVie Inc., F. Hoffmann-La Roche AG, Takeda Pharmaceuticals Company Limited, GSK Plc., Tillotts Pharma AG, Novartis AG, Salix Pharmaceuticals, FERRING B.V., Viatris Inc., and Dr. Falk Pharma GmbH.

Mesalazine is used to treat ulcerative colitis and Crohn's disease and other types of inflammatory bowel disease. Mesalazine is also known as mesalamine or 5-aminosalicylic acid (5-ASA). It belongs to a group of medicines called aminosalicylates that help to reduce redness and swelling (inflammation). It suppresses the production of chemical messengers (prostaglandins) that cause inflammation (swelling) in the intestines. This reduces ulceration, bleeding, and stomach pain, and prevents future flare-ups of the disease. Mesalazine is a bowel-specific aminosalicylate drug that is metabolized in the gut after oral administration and has predominant actions, flatulence, headache, vomiting, diarrhea, nausea, abdominal pain, rash, and dyspepsia are the common side effects of mesalazine drug. Ulcerative colitis and Crohn’s disease are chronic relapsing conditions generally characterized by repetitive cycles of active and quiescent disease. Intestinal inflammation can result in bleeding and anemia, perforation with abscess or fistula formation, or subsequent fibrosis with intestinal obstruction. Mesalazine is only available on prescription and comes as tablets, granules, rectal foam, suppositories, and enemas.   

Market Dynamics

Increasing adoption of inorganic strategies such as agreement by key market players is expected to drive China mesalazine market growth over the forecast period. For instance, in December 2020, Takeda Pharmaceutical Company Limited, a pharmaceutical company, announced that it had agreed with Hasten Biopharmaceutic Co., Ltd., a pharmaceutical company, to divest a portfolio of non-core prescription pharmaceutical products sold in China. Takeda Pharmaceutical Company Limited will receive US$ 322 million, subject to customary legal and regulatory closing conditions.

Key features of the study:

  • This report provides an in-depth analysis of China mesalazine market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in China mesalazine market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Zhejiang Hengkang Pharmaceutical Co. Ltd., Jiangsu Jubang Pharmaceutical Co., Ltd., ALP Pharm Beijing Co., Ltd., Shanghai Pharmaceuticals Holding Co Ltd., Heilongjiang Tianhong Pharmaceutical Co., Ltd., AbbVie Inc., F. Hoffmann-La Roche AG, Takeda Pharmaceuticals Company Limited, GSK Plc., Tillotts Pharma AG, Novartis AG, Salix Pharmaceuticals, FERRING B.V., Viatris Inc., and Dr. Falk Pharma GmbH
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • China mesalazine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing China mesalazine market

Detailed Segmentation:

  • China Mesalazine Market, By Route of Administration:
    • Oral
    • Rectal
  • China Mesalazine Market, By Application:
    • Ulcerative Colitis
    • Crohn's Disease
    • Inflammatory Bowel Disease
  • China Mesalazine Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Company Profiles
    • Zhejiang Hengkang Pharmaceutical Co. Ltd.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Jiangsu Jubang Pharmaceutical Co., Ltd.
    • ALP Pharm Beijing Co., Ltd.
    • Shanghai Pharmaceuticals Holding Co Ltd.
    • Heilongjiang Tianhong Pharmaceutical Co., Ltd.
    • AbbVie Inc.
    • Hoffmann-La Roche AG
    • Takeda Pharmaceuticals Company Limited
    • GSK Plc.
    • Tillotts Pharma AG
    • Novartis AG
    • Salix Pharmaceuticals
    • FERRING B.V.
    • Viatris Inc.
    • Falk Pharma GmbH

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

China mesalazine market is estimated to be valued at US$ 51.6 million in 2022 and is expected to exhibit a CAGR of 3.1% between 2022 and 2030.
Increasing inorganic strategies such as product launches by key market players is expected to drive the market.
Ulcerative colitis is the leading application segment in market
The availability of alternatives for mesalazine is expected to hamper the market over the forecast period
Major players operating in market include Zhejiang Hengkang Pharmaceutical Co. Ltd., Jiangsu Jubang Pharmaceutical Co., Ltd., ALP Pharm Beijing Co., Ltd., Shanghai Pharmaceuticals Holding Co Ltd., Heilongjiang Tianhong Pharmaceutical Co., Ltd., AbbVie Inc., F. Hoffmann-La Roche AG, Takeda Pharmaceuticals Company Limited, GSK Plc., Tillotts Pharma AG, Novartis AG, Salix Pharmaceuticals, FERRING B.V., Viatris Inc., and Dr. Falk Pharma GmbH.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo